Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Takeda to License CCR5 Antagonists to Tobira Therapeutics
August 20, 2007
- Takeda, Santhera Extend Marketing Collaboration in EU for SNT-MC17
August 20, 2007
- Astellas Reorganizes European Business Functions
August 20, 2007
- REGULATORY NEWS IN BRIEF(1)
August 20, 2007
- Chugai: Half-Year Sales Up 12%, Ordinary Profits Up 30.5%
August 20, 2007
- REGULATORY NEWS IN BRIEF(2)
August 20, 2007
- Takeda, Taiyo in Dispute over Recall of Pansporin
August 20, 2007
- Nippon Shinyaku to Create "Monitor System" to Have New Compounds Assessed by Outside Experts
August 20, 2007
- BUSINESS NEWS IN BRIEF
August 20, 2007
- WC6 on Alternatives and Animal Use in Life Sciences to Be Held in Tokyo
August 20, 2007
- TOPICS／ACTOS Offers Safety Profile: Takeda
August 20, 2007
- R&D NEWS IN BRIEF
August 20, 2007
- TOPICS／Avandia to Remain Available in the US: GSK
August 20, 2007
- Korosho Starts Drafting New Vision for Medical Device Industry
August 20, 2007
- SURVEY／Once-Daily Bisphosphonate Formulations Preferred to Once-Weekly Formulations
August 20, 2007
- MEDICAL DEVICE NEWS IN BRIEF
August 20, 2007
- JGPMA to Enhance Reliability of Generics: Mr Sawai
August 20, 2007
- Candidates Recommended by JMA, JPA Lose Seats in Upper House
August 20, 2007
- JMA Presents Strong Objection to the Use of Generics: Chuikyo
August 20, 2007
- LDP Must Review Its Medical Expenditure Curtailment Policy: JMA
August 20, 2007
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…